EGFR mutations primarily rely on direct intervention from the microenvironment: they upregulate MMPs (such as MMP-9) to degrade components of the blood–brain barrier [25], compromising its integrity, while simultaneously secreting chemokines to mediate the directional migration of tumor cells towards brain tissue. The gene discussed is EGFR; the disease is neoplasm.